Ifabotuzumab ELISA Kit (KDD82501)

Colorimetric

Plasma, Serum

Quantitative

0.31-5 μg/mL

0.156 μg/ml

CV<20%

80-120%

2-8 ℃

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Ifabotuzumab (formerly KB004) is a first-in-class therapeutic non-fucosylated IgG1 (human f-allotype) monoclonal antibody being developed by Humanigen (formerly KaloBios Pharmaceuticals) for the treatment of cancer. The drug was licensed from the Ludwig Institute for Cancer Research. The molecule contains a human antibody constant region with V-regions that are 92% identical to human germ-line sequences. Ifabotuzumab targets the ephrin type-A receptor 3 (EphA3) tyrosine kinase. In non-clinical studies, Ifabotuzumab demonstrated potent ex-vivo cell killing of EphA3+ tumor cells obtained from patients with hematologic malignancies.